- Home
- MGNX vs CLPR Comparison
MGNX vs CLPR Comparison
Compare MGNX & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- CLPR
- Stock Information
- Founded
- MGNX 2000
- CLPR 2015
- Country
- MGNX United States
- CLPR United States
- Employees
- MGNX N/A
- CLPR 171
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- CLPR Real Estate Investment Trusts
- Sector
- MGNX Health Care
- CLPR Real Estate
- Exchange
- MGNX Nasdaq
- CLPR Nasdaq
- Market Cap
- MGNX 70.3M
- CLPR 57.8M
- IPO Year
- MGNX 2013
- CLPR 2017
- Fundamental
- Price
- MGNX $1.26
- CLPR $3.67
- Analyst Decision
- MGNX Hold
- CLPR Sell
- Analyst Count
- MGNX 10
- CLPR 2
- Target Price
- MGNX $6.83
- CLPR N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- CLPR 212.1K
- Earning Date
- MGNX 05-08-2025
- CLPR 05-06-2025
- Dividend Yield
- MGNX N/A
- CLPR 10.30%
- EPS Growth
- MGNX N/A
- CLPR N/A
- EPS
- MGNX N/A
- CLPR N/A
- Revenue
- MGNX $149,962,000.00
- CLPR $148,775,000.00
- Revenue This Year
- MGNX N/A
- CLPR N/A
- Revenue Next Year
- MGNX $80.86
- CLPR N/A
- P/E Ratio
- MGNX N/A
- CLPR N/A
- Revenue Growth
- MGNX 155.26
- CLPR 7.65
- 52 Week Low
- MGNX $0.99
- CLPR $3.38
- 52 Week High
- MGNX $17.24
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- CLPR 44.08
- Support Level
- MGNX $1.10
- CLPR $3.60
- Resistance Level
- MGNX $1.34
- CLPR $3.82
- Average True Range (ATR)
- MGNX 0.13
- CLPR 0.23
- MACD
- MGNX 0.04
- CLPR 0.01
- Stochastic Oscillator
- MGNX 77.14
- CLPR 41.59
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.